额外角色补偿计划角色对英国处方模式和患者满意度的影响:回顾性小组数据分析
Catia Nicodemo1, Chris Salisbury2, Stavros Petrou3
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; professor of health economics, Brunel University of London, London, UK.
英格兰的"额外角色补偿计划" (ARRS) 与一般实践中更少的处方和更高的患者满意度有关. 该倡议旨在通过引入新角色来改善初级保健的准入.
科学领域:
- 初级保健研究研究初级保健研究
- 医疗服务管理 医疗服务管理
- 一般实践 劳动力研究 劳动力研究
背景情况:
- 额外角色补偿计划 (ARRS) 于2019年在英格兰推出,以提高通用实践能力.
- 该计划旨在为初级保健机构招聘26,000名额外的员工.
- 提高通用实践的获取是推动ARRS实施的政府关键目标之一.
研究的目的:
- 评估ARRS资助人员对处方率的影响.
- 评估ARRS工作人员对患者满意度水平的影响.
- 分析新角色的引入与初级保健服务提供之间的关联.
主要方法:
- 使用2018-2022年的数据进行回顾性面板数据分析.
- 包括来自英格兰6000多家全科医院的数据.
- 使用线性回归模型来确定关联,控制相关变量.
主要成果:
- 在较大的实践中,每位患者的全职全科医生 (GP) 较少,ARRS角色更为普遍.
- 在ARRS工作人员和降低处方率 (β = -0.52,P<0.001) 之间发现了显著的关联.
- 在ARRS工作人员和患者满意度增加之间发现了显著的关联 (β = 3.2,P<0.001).
结论:
- 该ARRS显示了积极的初级保健影响的潜力,包括更低的处方率和更高的患者满意度.
- 建议进行进一步的研究,以调查对患者结果和成本的长期影响.
- 识别和解决ARRS的实施障碍对于最大限度地发挥其益处至关重要.
更多相关视频
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
06:16Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
相关概念视频
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
The Placebo Effect
Current Trends in Nursing II
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
